Cullinan Therapeutics (CGEM) Cash from Operations: 2020-2024
Historic Cash from Operations for Cullinan Therapeutics (CGEM) over the last 5 years, with Dec 2024 value amounting to -$145.3 million.
- Cullinan Therapeutics' Cash from Operations rose 27.43% to -$18.1 million in Q4 2023 from the same period last year, while for Dec 2023 it was -$134.3 million, marking a year-over-year decrease of 6.01%. This contributed to the annual value of -$145.3 million for FY2024, which is 8.21% down from last year.
- Cullinan Therapeutics' Cash from Operations amounted to -$145.3 million in FY2024, which was down 8.21% from -$134.3 million recorded in FY2023.
- Cullinan Therapeutics' 5-year Cash from Operations high stood at -$29.8 million for FY2020, and its period low was -$145.3 million during FY2024.
- In the last 3 years, Cullinan Therapeutics' Cash from Operations had a median value of -$134.3 million in 2023 and averaged -$135.4 million.
- Data for Cullinan Therapeutics' Cash from Operations shows a maximum YoY tumbled of 191.63% (in 2022) over the last 5 years.
- Cullinan Therapeutics' Cash from Operations (Yearly) stood at -$29.8 million in 2020, then plummeted by 45.89% to -$43.4 million in 2021, then crashed by 191.63% to -$126.7 million in 2022, then declined by 6.01% to -$134.3 million in 2023, then declined by 8.21% to -$145.3 million in 2024.